

Sanofi  
Form 6-K  
May 02, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2013

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

Edgar Filing: Sanofi - Form 6-K

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In April and May 2013, Sanofi issued the statements attached hereto as Exhibit 99.1 to Exhibit 99.5 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated May 2, 2013: First quarter 2013 Results
Exhibit 99.2	Press release dated May 2, 2013: Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization
Exhibit 99.3	Press release dated April 25, 2013: Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
Exhibit 99.4	Press release dated April 22, 2013: Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended March 31, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 2, 2013

SANOFI

By /S/ John Felitti  
Name: John Felitti  
Title: Associate Vice President, Corporate Law, Financial & Securities  
Law

3

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated May 2, 2013: First quarter 2013 Results
Exhibit 99.2	Press release dated May 2, 2013: Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization
Exhibit 99.3	Press release dated April 25, 2013: Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
Exhibit 99.4	Press release dated April 22, 2013: Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended March 31, 2013